Q4 FY2026 · ended Mar 31, 2026 · Revenue $0 · Filed Aug 14, 2026
Protagenic Therapeutics, Inc.\new (PTIX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q4 of fiscal 2026, the quarter ended Mar 31, 2026, it reported revenue of $0 and net income of $5.1 million.
Revenue
$0
Net income
$5.08M
+130.0% vs prior quarter
Operating cash flow
$265,533
+152.1% vs prior quarter
Free cash flow
—
EPS
$2.70
+137.2% vs prior quarter
Dividend per share
None
Shares outstanding
1.81M
+207.4% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PTIX (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1022899
- Former names
- Atrinsic, Inc. (until Jun 20, 2016); NEW MOTION, INC. (until Jun 30, 2009); MPLC, Inc. (until Apr 2, 2007); MILLBROOK PRESS INC (until May 23, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Mar 31, 2026 |
Q3 FY2026 Dec 31, 2025 |
Q2 FY2026 Sep 30, 2025 |
Q1 FY2026 Jun 30, 2025 |
Q1 FY2025 Mar 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$120,331 | -$925,103 | -$1.1M | -$1.2M | -$1.4M |
| Net income | $5.1M | $2.2M | -$869,496 | -$5.1M | -$1.4M |
| Diluted EPS | $2.70 | $1.14 | -$0.47 | -$1.37 | -$2.75 |
| Operating cash flow | $265,533 | -$509,667 | -$811,525 | -$1.8M | -$1.1M |
| Total assets | $3.7M | $4.4M | $5.0M | $6.5M | $89,093 |
| Total liabilities | $1.0M | $6.8M | $9.7M | $10.5M | $5.0M |
| Stockholders' equity | $2.6M | -$2.4M | -$4.7M | -$4.0M | -$5.0M |
| Cash and investments | $1.5M | $2.2M | $2.7M | $4.1M | $14,531 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 20, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 10-K | Annual report | Aug 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 7, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Mar 9, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 3, 2026 | Feb 3, 2026 |
All 705 Protagenic Therapeutics, Inc.\new SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.